Valuation: Harrow, Inc.

Market Cap 1.46B 1.27B 1.18B 1.09B 2.05B 139B 2.08B 13.94B 5.46B 69.26B 5.47B 5.35B 228B P/E 2026 *
168x
P/E 2027 * 16.7x
Enterprise Value 1.46B 1.27B 1.18B 1.09B 2.05B 139B 2.08B 13.94B 5.46B 69.26B 5.47B 5.35B 228B EV / Sales 2026 *
4.18x
EV / Sales 2027 * 2.82x
Free-Float
84.53%
Yield 2026 *
-
Yield 2027 * -
1 day+0.58%
1 week+0.13%
Current month+1.55%
1 month-12.37%
3 months-2.06%
6 months-16.59%
Current year-19.65%
1 week 37.18
Extreme 37.18
39.72
1 month 36.25
Extreme 36.25
47.5
Current year 28.54
Extreme 28.5401
54.85
1 year 28.54
Extreme 28.5401
54.85
3 years 7.6
Extreme 7.6
59.23
5 years 5.4
Extreme 5.4
59.23
10 years 1.35
Extreme 1.35
59.23
Manager TitleAgeSince
Chief Executive Officer 53 2011-12-16
President 43 2025-08-20
Compliance Officer - 2023-09-30
Director TitleAgeSince
Chairman 53 2021-08-18
Director/Board Member 57 2022-03-30
Director/Board Member 71 2024-01-25
Date Insider Type Main position Quantity % Market Cap.
2/27/26
Opaleye Management, Inc.
SellCompany 5,000 0.0135%
1/30/26 Free

CHIEF COMMERCIAL OFFICER

40,000 0.1080%
1/30/26 Other

CHIEF COMMERCIAL OFFICER

30,000 0.0810%
Change 5-day change 1-year change 3-year change Capi.($)
+0.58%+0.13%+17.80%+89.10% 1.46B
+0.71%-7.74%+46.44%+150.54% 1T
-0.51%-5.99%+46.61%+48.35% 613B
+0.32%-6.71%+24.51%+66.20% 433B
+1.18%-2.50%+40.67%+35.33% 350B
+0.31%-4.39%+31.82%+39.98% 292B
+1.87%-9.63%+5.01%+7.19% 239B
+1.93%-8.29%-1.73%-42.05% 206B
+0.91%-3.47%+25.67%+55.98% 204B
+0.08%-2.95%+13.84%+65.68% 163B
Average +0.70%-3.06%+25.07%+51.63% 350.19B
Weighted average by Cap. +0.54%-4.34%+33.56%+70.88%

Financials

2026 *2027 *
Net sales 348M 303M 283M 260M 489M 33.21B 498M 3.33B 1.31B 16.56B 1.31B 1.28B 54.63B 517M 450M 420M 385M 727M 49.32B 739M 4.95B 1.94B 24.6B 1.94B 1.9B 81.13B
Net income 9.18M 7.98M 7.45M 6.84M 12.9M 875M 13.12M 87.84M 34.4M 436M 34.49M 33.72M 1.44B 93.99M 81.68M 76.26M 70.01M 132M 8.96B 134M 899M 352M 4.47B 353M 345M 14.73B
Net Debt - -
Logo Harrow, Inc.
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Employees
373
Date Price Change Volume
26-08-04 US$39.45 +0.92% 41,637
26-08-03 US$39.09 +0.83% 400,523
26-07-31 US$38.77 -0.44% 261,659
26-07-30 US$38.94 +0.67% 291,055
26-07-29 US$38.68 -1.63% 362,726
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
39.09USD
Average target price
67.75USD
Spread / Average Target
+73.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HROW Stock